Trials / Completed
CompletedNCT03209518
Special Drug Use Surveillance of Leuprorelin for Injection Kit 22.5 mg in "Premenopausal Breast Cancer"
Special Drug Use Surveillance of Leuplin PRO for Injection Kit 22.5 mg in "Premenopausal Breast Cancer"
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 312 (actual)
- Sponsor
- Takeda · Industry
- Sex
- Female
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of this survey is to evaluate the safety in patients with premenopausal breast cancer receiving Leuprorelin in the routine clinical setting.
Detailed description
The drug being tested in this survey is called Leuprorelin for Injection Kit 22.5 mg. Leuprorelin is being tested to treat people who have premenopausal breast cancer. This survey will look at the safety in patients with premenopausal breast cancer receiving the drug in the routine clinical setting. The survey will enroll approximately 300 patients. \- Leuprorelin This multi-center survey will be conducted in Japan.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Leuprorelin acetate | Leuplin PRO for Injection Kit 22.5 mg |
Timeline
- Start date
- 2016-03-18
- Primary completion
- 2018-10-10
- Completion
- 2018-10-10
- First posted
- 2017-07-06
- Last updated
- 2019-11-01
- Results posted
- 2019-11-01
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT03209518. Inclusion in this directory is not an endorsement.